Sustainability at CSL

CSL develops and delivers innovative medicines that save lives, protect public health and help people with life-threatening medical conditions live full lives. CSL holds more than 7,000 active and valid product registrations (including varying vial sizes) in over 100 countries, supporting newborns through to the elderly. Our support for patient groups and their programs helps to raise awareness and diagnosis of rare and serious diseases, improve access to our life-saving therapies and protect public health.

CSL strives to create an open and trusting work environment characterised by equal opportunity, as well as an inclusive, collaborative and values-based culture. We rely on our people’s unique perspectives, ideas, capabilities and experiences to deliver for our business, our patients and our shareholders. We believe inclusion and belonging are crucial to strong business growth and performance.

Our product portfolio focuses on innovation in new products, improved products and manufacturing expertise, thereby ensuring our continued growth. We enter into collaborative partnerships to further the science and prospects for successful product development. These partnerships often result in shared knowledge, intellectual property or products. 

At CSL, we recognise that responsible management and efficient use of natural resources is a key to our sustainable growth and our ability to enable efficient and reliable supply of our life-saving medicines. We believe this makes us a stronger, more resilient business better prepared to navigate the future.

In 2022, we announced enterprise emissions reduction targets. In alignment with the Science-Based Targets initiative (SBTi). At the end of May 2025, the SBTi approved CSL’s near-term science-based emissions reduction targets. These are:

• CSL commits to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% by FY2030 (from a FY2021 base year)¹.
• CSL commits that 73.1% of CSL’s suppliers by emissions – covering Scope 3 categories: purchased goods and services, capital goods, upstream transportation and distribution, business travel, and downstream transportation and distribution – will have science-based targets by FY2030.

¹ In 2022, CSL announced its initial target to reduce emissions associated with its own operations by 40%. This target has since been updated to 42% to align with the SBTi’s reporting period for calendar years. CSL’s Scope 3-related target, approved by the SBTi (as outlined above), is part of CSL’s broader intention to engage suppliers who account for 67% of all CSL’s total Scope 3 emissions. CSL aims for these suppliers to have Scope 1 and 2 emissions reduction targets aligned^* with the SBTi. This broader intention applies to suppliers across all Scope 3 categories.

The target boundary includes land-related emissions and removals from bioenergy feedstocks.

^* Either the supplier has SBTi-validated targets, or CSL has conducted due diligence to confirm that the supplier’s targets meet SBTi criteria.